Algeta licenses Alpharadin to Bayer in $800 million deal
This article was originally published in Scrip
Executive Summary
Bayer Healthcare is to pay Algeta up to $800 million for the worldwide commercialisation rights to its anticancer Alpharadin (ATI-BC-1).